Vasogen ACCLAIM trial
This article was originally published in The Gray Sheet
Executive Summary
Double-blind, placebo-controlled Phase III study examining impact of firm's Celacade immune modulation technology on the risk of death and cardiovascular hospitalization in patients with advanced chronic heart failure has reached full enrollment of 2,000 patients, Vasogen announces May 5. Quest Diagnostics has invested in Celacade through a joint U.S. commercialization pact (1"The Gray Sheet" Nov. 26, 2001, p. 33)...